Brennan Linsley / AP

The D.C. Court of Appeals decided today it will hear the Consumer Financial Protection Bureau's appeal en banc in May, per the ABA. Today's ruling vacated the divided three-judge court ruling from October 2016 in PHH Mortgage v. Consumer Financial Protection Bureau that the structure was unconstitutional.

The ruling made it so the president could remove the CFPB director at will: at any time and for any reason, which stripped the bureau of its independence.

Why this matters: Now Trump will be unable to remove CFPB director Richard Cordray before his term is up, allowing him to finish up the rest of his term through 2018. It is possible that Trump could remove the director for cause, but an expert on constitutional law and appellate procedure told Axios this is "unlikely to happen" since "there's not precedent on that."

What to expect: The legal expert also said it would be surprising if there was a decision by the end of the year and to expect a decision either early on next year or mid next year. In the meantime, the CFPB will operate as usual.

One caveat: If Congress amends the Dodd-Frank Act, it could render the case moot.

Go deeper

Pelosi, Schumer demand postmaster general reverse USPS cuts ahead of election

Schumer and Pelosi. Photo: Alex Wong/Getty Images

House Speaker Nancy Pelosi (D-Calif.) and Senate Minority Leader Chuck Schumer sent a letter to Postmaster General Louis DeJoy on Thursday calling for the recent Trump appointee to reverse operational changes to the U.S. Postal Service that "threaten the timely delivery of mail" ahead of the 2020 election.

Why it matters: U.S. mail and election infrastructure are facing a test like no other this November, with a record-breaking number of mail-in ballots expected as Americans attempt to vote in the midst of a pandemic.

2 hours ago - Science

CRISPR co-discoverer on the gene editor's pandemic push

Photo illustration: Aïda Amer/Axios. Photos: Brian Ach/Getty Images for Wired and BSIP/UIG via Getty Images

The coronavirus pandemic is accelerating the development of CRISPR-based tests for detecting disease — and highlighting how gene-editing tools might one day fight pandemics, one of its discoverers, Jennifer Doudna, tells Axios.

Why it matters: Testing shortages and backlogs underscore a need for improved mass testing for COVID-19. Diagnostic tests based on CRISPR — which Doudna and colleagues identified in 2012, ushering in the "CRISPR revolution" in genome editing — are being developed for dengue, Zika and other diseases, but a global pandemic is a proving ground for these tools that hold promise for speed and lower costs.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Eniola Odetunde/Axios

  1. Global: Total confirmed cases as of 5 p.m. ET: 18,912,947 — Total deaths: 710,318— Total recoveries — 11,403,473Map.
  2. U.S.: Total confirmed cases as of 5 p.m. ET: 4,867,916 — Total deaths: 159,841 — Total recoveries: 1,577,851 — Total tests: 58,920,975Map.
  3. Politics: Pelosi rips GOP over stimulus negotiations: "Perhaps you mistook them for somebody who gives a damn" — Ohio Gov. Mike DeWine tests positive.
  4. Public health: Majority of Americans say states reopened too quicklyFauci says task force will examine aerosolized spread.
  5. Business: The health care sector imploded in Q2More farmers are declaring bankruptcyJuly's jobs report could be an inflection point for the recovery.
  6. Sports: Where college football's biggest conferences stand on playing.